Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Behind Cephalon's Numbers: a Big Cancer Bet and Signs of Skepticism
- The FDA delivered to Cephalon a letter yesterday saying it would not approve expanded indications for its pain drug Fentora until the company gave it more information on how it would prevent the drug from being abused. Even though the Fentora situation is fixable, it's just the sort of headache...
- Blog posts 2008-09-16
Additional Resources
- Cephalon, Inc. Q2 2008 Earnings Call
- Question-and-Answer SessionThe question and answer session will be conducted electronically. [Operator Instructions]. We will pause just a moment. We'll take our first question from Jim Birchenough with Lehman Brothers. Jim Birchenough - Lehman Brothers Hi, guys. Congratulations on the quarter. I want to start-off with a big picture question...
- Earnings calls 2008-07-29
- Cephalon, Inc. to Acquire Amrix(R) - a Eurand Diffucaps(R) Product.
- MILAN, Italy and DAYTON, Ohio, August 23 /PRNewswire/ -- MILAN, Italy and DAYTON, Ohio, August 23 /PRNewswire/ --
- Research articles 2007-08-23
- Cephalon, Inc. Q4 2007 Earnings Call Transcript
- Question-and-Answer Session[Operator Instructions]. Our first question will come Greg Gilbert with Merrill Lynch. Greg Gilbert - Merrill Lynch Thanks. I have a couple. First for Kevin. Can you help us with what level of TREANDA expense you filed in for '08, if possible broken down between launch related versus...
- Earnings calls 2008-02-12
- Cephalon Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator We will take our first question from Jim Birchenough with Barclays. Jim Birchenough - Barclays Just wondering on the PROVIGIL number for the quarter, it was down 10%. I'm having trouble reconciling that with the price increase and what seemed to be relatively flat volume trends. Could...
- Earnings calls 2009-05-05
- << Previous
- page 1 of 1
- Next >>
